

C-CARE (MAURITIUS) LTD AND ITS SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS FOR
THE 9 MONTHS ENDED 31 MARCH 2022



UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF
PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE 9 MONTHS ENDED 31 MARCH 2022

THE GROUP

	Unaudited Quarter Ended 31 March 2022	Unaudited Quarter Ended 31 March 2021	Unaudited 9 Months Ended 31 March 2022	Unaudited 9 Months Ended 31 March 2021
	Rs'000	Rs'000	Rs'000	Rs'000
Turnover	791,256	607,956	2,259,920	1,808,649
Earnings Before Interests, Taxation, Depreciation and Amortisation (EBITDA)	183,100	110,509	546,317	380,661
Depreciation and amortisation	(36,170)	(27,448)	(101,033)	(88,174)
Earnings Before Interests and Taxation (EBIT)	146,929	83,061	445,284	292,488
Net finance cost	(14,189)	(15,610)	(44,009)	(45,518)
Profit before taxation	132,740	67,451	401,275	246,970
Taxation	(22,456)	-	(69,316)	424
Profit after tax	110,285	67,451	331,960	247,394
Attributable to:				
Equity holders	110,285	67,451	331,960	247,394
Earnings per share				
Earnings attributable to equity holders	110,285	67,451	331,960	247,394
Number of shares in issue ('000)	569,941	569,941	569,941	569,941
Earnings per share (Rs/Cs)	0.19	0.12	0.58	0.43

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF FINANCIAL POSITION AS AT 31 MARCH 2022

THE GROUP

	Unaudited As at 31 March 2022	Audited As at 30 Jun 2021
	Rs'000	Rs'000
ASSETS		
Non-current assets	2,130,778	2,194,987
Current assets	934,693	625,987
TOTAL ASSETS	3,065,471	2,820,974
EQUITY AND LIABILITIES		
Equity attributable to:		
Equity holders	1,157,156	825,196
TOTAL EQUITY	1,157,156	825,196
Non-current liabilities	1,265,008	1,266,924
Current liabilities	643,308	728,854
TOTAL EQUITY AND LIABILITIES	3,065,471	2,820,974

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN
EQUITY FOR THE 9 MONTHS ENDED 31 MARCH 2022

Attributable to equity holders

THE GROUP	Issued Capital	Revaluation reserve	Retained Earnings	Total Equity
	Rs'000	Rs'000	Rs'000	Rs'000
At 1 Jul 20	289,801	265,454	247,296	802,552
Dividend	-	-	(113,988)	(113,988)
Profit for the period	-	-	247,394	247,394
At 31 March 2021	289,801	265,454	380,702	935,958
At 1 July 2021	289,801	265,495	269,900	825,196
Profit for the period	-	-	331,960	331,960
At 31 March 2022	289,801	265,495	601,860	1,157,156

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS FOR THE 9 MONTHS
ENDED 31 MARCH 2022

	Unaudited Period Ended 31 March 2022	Unaudited Period Ended 31 March 2021
	Rs'000	Rs'000
Net Cash flows from operating activities	424,581	391,171
Net Cash flows used in investing activities	(97,806)	(120,047)
Net Cash flows used in financing activities	(160,607)	(208,656)
Increase/(Decrease) in cash and cash equivalent	166,168	62,468
MOVEMENT IN CASH AND CASH EQUIVALENT		
At the beginning of the period	234,852	156,689
Movement during the period	166,168	62,468
At the end of the period	401,019	219,157

NOTES

The abridged financial statements for the nine months ended 31 March 2022 are unaudited and have been prepared using the same accounting policies as in the audited financial statements for the year ended 30 June 2021.

The above results is a consolidated view of the operations of Clinique Darné, Wellkin Hospital and C-Lab including Le Café du Volcan Ltée and C-Care North Ltd, wholly owned subsidiaries of C-Care (Mauritius) Ltd.

During the quarter, the group maintained its performance, still mainly driven by revenue from COVID-19 tests, despite a fall noticed at the end of the Quarter with the change in Covid protocols worldwide.

The Board of Directors of C-Care (Mauritius) Ltd accepts full responsibility for the accuracy of the information contained in this report.

By Order of the Board

CIEL Corporate Services Ltd
Company Secretary

Date: 11 May 2022

BRN: C07002054

This report is pursuant to Rule 17 of the Development & Enterprise Market and Securities Act 2005.

Copies of the Unaudited Condensed Financial Statements are available to the public free of charge at the Company's registered office: 5th Floor, Ebène Skies, rue de l'Institut, Ebène.

The statement of direct and indirect interests of insiders pursuant to Rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007 is available free of charge at the registered office of the Company.